Upstream Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UPB research report →
Range $15 – $25
Price Chart
About the company
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor.
- CEO
- E. Rand Sutherland
- IPO
- 2024
- Employees
- 75
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on UPB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $372.78M
- P/E
- -2.36
- PEG
- 0.07
- P/S
- 118.04
- P/B
- 1.38
- EV/EBITDA
- -1.88
- Div Yield
- 0.00%
- Gross Margin
- 98.45%
- Op Margin
- -5382.65%
- Net Margin
- -4955.67%
- ROE
- -48.40%
- ROIC
- -62.51%
Latest fiscal year · YoY change
- Revenue
- $2.85M+20.4%
- Gross Profit
- $2.85M+20.4%
- Op Income
- $-160,361,000
- Net Income
- $-143,443,000-128.4%
- EPS
- $-2.66-78.5%
- OCF Growth
- -125.2%
- FCF Growth
- -123.3%
- 52W High
- $33.68
- 52W Low
- $5.85
- 50D MA
- $6.83
- 200D MA
- $14.95
- Beta
- 1.27
- RSI (14)
- 48
- Avg Volume
- 606.74K
No earnings-call transcripts are available for UPB yet.
- Free Float
- 36.9%
- Shares Outstanding
- 54.42M
- Float Shares
- 20.08M
of shares held by institutions
138 13F filers
Buy/sell ratio 1.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.39M | ▼ 54.11K |
| California State Teachers Retirement System | 39.66K | ▲ 25.01K |
| Cwm, LLC | 3.88K | ▲ 523 |
Held by 152 ETFs
Biggest fund positions in UPB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | GRAY MICHAEL | sell | 853 |
| Jun 16, 26 | Sutherland Everett Rand | sell | 2,095 |
| Jun 16, 26 | Houghton Adam | sell | 700 |
| Jun 16, 26 | Deykin Aaron | sell | 895 |
| Jun 16, 26 | Ambrose Allison | sell | 477 |
| Jun 9, 26 | Ruddy Marcella K. | other | 17,096 |
| Jun 9, 26 | Renaud Ronald C JR | other | 17,096 |
| Jun 9, 26 | Fleming Harold Edward | other | 17,096 |
| Jun 9, 26 | Beckman Daniella | other | 17,096 |
| Jun 9, 26 | Ratcliffe Liam | other | 17,096 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our UPB coverage
Recent articles, reports, and earnings notes.
No research on UPB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UPB report →Fannie Mae Announces Sale of Non-Performing Loans
gurufocus.com · Aug 19
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
zacks.com · Aug 11
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Jul 14
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction
gurufocus.com · Jun 29
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
globenewswire.com · Jun 14
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
businesswire.com · Jun 12
Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com · Jun 10
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
globenewswire.com · Jun 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.